Jolanda Howe Sells 477 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 477 shares of the firm's stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $49.08, for a total value of $23,411.16. Following the completion of the sale, the senior vice president directly owned 2,426 shares in the company, valued at approximately $119,068.08. The trade was a 16.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Jolanda Howe also recently made the following trade(s):

• On Wednesday, July 2nd, Jolanda Howe sold 564 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.25, for a total value of $27,213.00.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM traded up $0.84 during midday trading on Friday, hitting $49.93. The company's stock had a trading volume of 216,684 shares, compared to its average volume of 465,058. The company has a market cap of $2.47 billion, a P/E ratio of -31.01 and a beta of 0.97. Mirum Pharmaceuticals, Inc. has a 12-month low of $33.64 and a 12-month high of $54.23. The business's 50 day simple moving average is $46.27 and its 200 day simple moving average is $45.44. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.04 and a current ratio of 3.22.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. The company had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 20.39% and a negative return on equity of 33.63%. Mirum Pharmaceuticals's quarterly revenue was up 61.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.54) EPS. On average, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in Mirum Pharmaceuticals by 4,555.0% in the 1st quarter. GAMMA Investing LLC now owns 5,586 shares of the company's stock valued at $252,000 after purchasing an additional 5,466 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Mirum Pharmaceuticals by 174.9% in the first quarter. SG Americas Securities LLC now owns 19,182 shares of the company's stock valued at $864,000 after acquiring an additional 12,204 shares during the last quarter. MPM Bioimpact LLC grew its position in Mirum Pharmaceuticals by 19.7% in the fourth quarter. MPM Bioimpact LLC now owns 589,579 shares of the company's stock worth $24,379,000 after acquiring an additional 96,856 shares during the period. AlphaQuest LLC increased its stake in Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after acquiring an additional 1,658 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth $277,000.

Analyst Ratings Changes

Several brokerages recently commented on MIRM. JMP Securities boosted their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $73.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Raymond James Financial reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. Finally, Wall Street Zen upgraded Mirum Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, June 28th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $65.50.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.